GIGaliya Isaeva

Galiya Isaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Galiya Isaeva has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Outcomes of Glofitamab therapy in CAR-T naïve Patients with Relapsed/Refractory Large B-cell lymphoma

    by Liudmila Fedorova, Natalia Mikhailova, Kirill Lepik, Vladislav Markelov, Andrey Chekalov, Olesya Smykova, Gayane Tumyan, Anastasia Semenova, Arman Arakelyan, Lev Butaev, et al.

  • Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report

    by G. K. Isaeva, M. M. Sarycheva, A. V. Vazhenin, A. V. Dubinina, K. M. Sheveleva, I. V. Makruta

    Background . Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases. Objective : to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy. Case presentation . A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle. Conclusion . Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).

  • Open Access

    Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program

    by Liudmila Valerevna Fedorova, N. B. Mikhailova, K. V. Lepik, A. M. Chekalov, O. G. Smykova, V. V. Markelov, G. S. Tumyan, A. A. Semenova, A. V. Arakelyan, L. S. Butaev, et al.

    BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.

  • The effectiveness of combined chemotherapy and immunotherapy, and the search for personalized approaches to treating advanced non-small cell lung cancer

    by G.K. Isaeva, M.I. Andrievskih, O.V. Berseneva, K.A. Shubina, D.K. Taskina, A.A. Erygina, V.A. Maltseva, I.V. Bakhareva, D.V. Menshchikov

    Lung cancer is one of the most significant health problems globally due to its high prevalence and mortality rates. Innovative treatment regimens are needed to improve survival rates and reduce mortality from this disease in clinical practice. Objective. To evaluate the effectiveness and safety of a combination therapy consisting of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) in the treatment of advanced non-small cell lung cancer (NSCLC). We also aim to identify the optimal patient population for whom this treatment regimen would be most beneficial in real-world clinical practice. Material and methods. A retrospective analysis of the medical records of 58 patients who received a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) at medical institutions in the Chelyabinsk region between January 2020 and November 2023 was conducted. Results. The median age of the 58 participants was 62 years (range: 38—84). The median duration of ABCP treatment was 11.3 months. Disease control (partial response or stable disease) was achieved in 84.2% (48) of patients. The median progression-free survival was 15.1 months (95% confidence interval (CI): 11.7—20.3). The mPFS among patients with brain metastases was 24.8 months (95% CI: 19.2—40.7)), p=0.05, and the median overall survival has not been reached yet. Conclusion. The study demonstrated that ABCP therapy shows high antitumor efficacy in real-world clinical settings for patients with advanced NSCLC. The objective response rate and progression-free and overall survival were equivalent or superior to those observed in the IMpower150 study. A subgroup analysis showed that patients with brain metastases can benefit from this combination therapy. The safety profile of ABCP was characterized by an acceptable profile with a very low incidence of immune-mediated adverse events. The data obtained allow us to consider ABCP combination therapy an effective strategy for the treatment of advanced NSCLC.